Muscle Weakness VAS scores were significantly lower in the CBTH group at the end of treatment ( z , 9.30 ; P < .001 ) and at the 6-month follow-up ( z , 3.10 ; P < .02 ) , but not at the 4-week follow-up ( P < .13 ) .